Subclinical atherosclerosis in patients with relapsing-remitting multiple sclerosis

被引:6
|
作者
Omerzu, Tomaz [1 ]
Magdic, Jozef [1 ]
Hojs, Radovan [2 ,3 ]
Potocnik, Uros [2 ]
Gorenjak, Mario [2 ]
Fabjan, Tanja Hojs [1 ,2 ]
机构
[1] Univ Med Ctr Maribor, Dept Neurol, Ljubljanska 5, Maribor 2000, Slovenia
[2] Univ Maribor, Fac Med, Taborska Ulica 8, Maribor 2000, Slovenia
[3] Univ Med Ctr Maribor, Dept Nephrol, Clin Internal Med, Ljubljanska 5, Maribor 2000, Slovenia
关键词
Inflammation; Neuroimmunology; Carotid intima media thickness; Cystatin C; Interleukin  6; CAROTID-ARTERY ATHEROSCLEROSIS; DISABILITY PROGRESSION; FUNCTIONAL COMPOSITE; INFLAMMATION; DISEASE; RISK; COMORBIDITY; DIALYSIS; COMMON;
D O I
10.1007/s00508-021-01862-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Multiple sclerosis is an inflammatory disorder of the central nervous system. Inflammation may create high susceptibility to subclinical atherosclerosis. The purpose of this study was to compare subclinical atherosclerosis and the role of inflammatory cytokines between the group of patients with relapsing-remitting multiple sclerosis (RRMS) and healthy controls matched for age and sex. Methods The study group consisted of 112 non-diabetic and non-hypertensive RRMS patients treated with disease modifying drugs (DMD) and the control group was composed of 51 healthy subjects. The common carotid artery (CCA) intima media thickness (IMT) was investigated. Serum levels of risk factors for atherosclerosis and inflammatory cytokines were also determined. Results The mean CCA IMT (0.572 +/- 0.131 mm vs. 0.571 +/- 0.114 mm) did not differ (p > 0.05) between patients and controls. The RRMS patients' CCA IMT was significantly correlated with serum interleukin 6 (IL-6) (p = 0.027), high-sensitivity C-reactive protein (hs-CRP) (p = 0.027), cystatin C (p < 0.0005), glucose (p = 0.031), cholesterol (p = 0.008), LDL (p = 0.021), erythrocyte sedimentation rate (p = 0.001) and triglyceride (p = 0.018) level. We fitted generalized linear models in order to assess the relationship between CCA IMT and IL-6 with adjustment for sex and age. The obtained results showed that adjusted for age (p < 0.001) and sex (p = 0.048) IL-6 serum levels statistically significantly (p = 0.009) predict CCA IMT only in the RRMS group. Conclusion The findings of the present study suggest that when treated with DMD RRMS might not be an independent risk factor for early atherosclerosis presenting with arterial wall thickening; however, the results suggest a significant association of IL-6 serum levels with CCA IMT only in the RRMS group.
引用
收藏
页码:40 / 47
页数:8
相关论文
共 50 条
  • [1] Subclinical atherosclerosis in patients with relapsing-remitting multiple sclerosis
    Tomaž Omerzu
    Jožef Magdič
    Radovan Hojs
    Uroš Potočnik
    Mario Gorenjak
    Tanja Hojs Fabjan
    Wiener klinische Wochenschrift, 2024, 136 : 40 - 47
  • [2] Comorbidity in in patients with relapsing-remitting multiple sclerosis.
    Somilo, O., V
    Makarov, S. O.
    Kalbus, O., I
    MEDICNI PERSPEKTIVI, 2024, 29 (03): : 137 - 143
  • [3] IVIg for relapsing-remitting multiple sclerosis: promises and uncertainties
    Bayry, Jagadeesh
    Hartung, Hans-Peter
    Kaveri, Srini V.
    TRENDS IN PHARMACOLOGICAL SCIENCES, 2015, 36 (07) : 419 - 421
  • [4] Peripheral oxidative stress in relapsing-remitting multiple sclerosis
    Tasset, Inmaculada
    Aguelera, Eduardo
    Sanchez-Lopez, Fernando
    Feijoo, Montserrat
    Giraldo, Ana I.
    Cruz, Antonio H.
    Gascon, Felix
    Tunez, Isaac
    CLINICAL BIOCHEMISTRY, 2012, 45 (06) : 440 - 444
  • [5] Correlates and trajectories of relapses in relapsing-remitting multiple sclerosis
    Young, Carolyn A.
    Rog, David J.
    Sharrack, Basil
    Tanasescu, Radu
    Kalra, Seema
    Harrower, Timothy
    Tennant, Alan
    Mills, Roger J.
    NEUROLOGICAL SCIENCES, 2024, 45 (05) : 2181 - 2189
  • [6] Screening of dysphagia in relapsing-remitting multiple sclerosis patients in Montenegro
    Erakovic, Jevto Lj
    Radulovic, Ljiljana B.
    Idrizovic, Zilha A.
    Roganovic, Milovan B.
    NEUROSCIENCES, 2021, 26 (04) : 331 - 338
  • [7] Facial emotion recognition in patients with relapsing-remitting multiple sclerosis
    Fereydouni, Soodabe
    Hadianfard, Habib
    Ashjazadeh, Nahid
    NEUROLOGY ASIA, 2019, 24 (04) : 327 - 332
  • [8] Natalizumab use in pediatric patients with relapsing-remitting multiple sclerosis
    Arnal-Garcia, Carmen
    Rosa Garcia-Montero, Ma
    Malaga, Ignacio
    Millan-Pascual, Jorge
    Oliva-Nacarino, Pedro
    Ramio-Torrenta, Lluis
    Oreja-Guevara, Celia
    EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2013, 17 (01) : 50 - 54
  • [9] Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis
    Hersh, Carrie M.
    Cohen, Jeffrey A.
    IMMUNOTHERAPY, 2014, 6 (03) : 249 - 259
  • [10] Alemtuzumab in the treatment of relapsing-remitting multiple sclerosis
    Fox, Edward J.
    EXPERT REVIEW OF NEUROTHERAPEUTICS, 2010, 10 (12) : 1789 - 1797